Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-181
2015-002782-32Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival in subjects with squamous cell carcinoma of the esophagus. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2015-002782-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002782-32.